These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 8121865)
1. Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas. Utas C; Kelestimur F; Boyaci A; Saglam A Postgrad Med J; 1993 Dec; 69(818):920-1. PubMed ID: 8121865 [TBL] [Abstract][Full Text] [Related]
2. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Verschoor L; Uitterlinden P; Lamberts SW; Del Pozo E Clin Endocrinol (Oxf); 1986 Nov; 25(5):555-60. PubMed ID: 2887309 [TBL] [Abstract][Full Text] [Related]
3. The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case. Tanaka Y; Funahashi H; Imai T; Naruse T; Suzumura K; Oda Y Surg Today; 2000; 30(6):541-3. PubMed ID: 10883468 [TBL] [Abstract][Full Text] [Related]
4. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Vezzosi D; Bennet A; Courbon F; Caron P Clin Endocrinol (Oxf); 2008 Jun; 68(6):904-11. PubMed ID: 18031316 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs. Simpson KW; Stepien RL; Elwood CM; Boswood A; Vaillant CR J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057 [TBL] [Abstract][Full Text] [Related]
6. Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism. Krentz AJ; Pace J; Somerville W; Clark PM; Nattrass M Postgrad Med J; 1993 Sep; 69(815):735-8. PubMed ID: 8255845 [TBL] [Abstract][Full Text] [Related]
7. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma. Timmer R; Koningsberger JC; Erkelens DW; Thijssen JH; Lips CJ; Koppeschaar HP Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592 [TBL] [Abstract][Full Text] [Related]
8. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Vezzosi D; Bennet A; Rochaix P; Courbon F; Selves J; Pradere B; Buscail L; Susini C; Caron P Eur J Endocrinol; 2005 May; 152(5):757-67. PubMed ID: 15879362 [TBL] [Abstract][Full Text] [Related]
10. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review. Hearn PR; Ahmed M; Woodhouse NJ Horm Res; 1988; 29(5-6):211-3. PubMed ID: 2851522 [TBL] [Abstract][Full Text] [Related]
11. Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995. Kung AW; Ma JT; Wang C; Fu KH; Lam KS; Yeung RT; Boey J Clin Endocrinol (Oxf); 1987 Oct; 27(4):469-73. PubMed ID: 2893673 [TBL] [Abstract][Full Text] [Related]
12. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report. Alberts AS; Falkson G S Afr Med J; 1988 Jul; 74(2):75-6. PubMed ID: 2899913 [TBL] [Abstract][Full Text] [Related]
13. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Romeo S; Milione M; Gatti A; Fallarino M; Corleto V; Morano S; Baroni MG Horm Res; 2006; 65(3):120-5. PubMed ID: 16479142 [TBL] [Abstract][Full Text] [Related]
14. A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma. Sandoval MA; Pagsisihan D; Berberabe A; Palugod-Lopez EG BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26994053 [TBL] [Abstract][Full Text] [Related]
15. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. van Schaik E; van Vliet EI; Feelders RA; Krenning EP; Khan S; Kamp K; Valkema R; van Nederveen FH; Teunissen JJ; Kwekkeboom DJ; de Herder WW J Clin Endocrinol Metab; 2011 Nov; 96(11):3381-9. PubMed ID: 21917872 [TBL] [Abstract][Full Text] [Related]
16. [Preoperative treatment of hypoglycemia caused by an insulinoma with the somatostatin analog SMS 201-995]. Sánchez García Cervigón P; Fernández Navarro JI; Salmerón de Diego J; Caballero Asensi A; Cornelio Hernández F; Jara Albarrán A Med Clin (Barc); 1987 Oct; 89(12):511-3. PubMed ID: 2890800 [No Abstract] [Full Text] [Related]
17. Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma. Fischbach J; Gut P; Matysiak-Grześ M; Klimowicz A; Gryczyńska M; Waśko R; Ruchała M Neuro Endocrinol Lett; 2012; 33(3):273-8. PubMed ID: 22635083 [TBL] [Abstract][Full Text] [Related]
18. Metabolic remission with octreotide in patients with insulinoma. von Eyben FE; Grodum E; Gjessing HJ; Hagen C; Nielsen H J Intern Med; 1994 Mar; 235(3):245-8. PubMed ID: 8120520 [TBL] [Abstract][Full Text] [Related]
19. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995. Glaser B; Rösler A; Halperin Y Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884 [TBL] [Abstract][Full Text] [Related]